Skip to main content
Journal cover image

Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.

Publication ,  Journal Article
Hendrickson, WK; Xie, G; Rahn, DD; Amundsen, CL; Hokanson, JA; Bradley, M; Smith, AL; Sung, VW; Visco, AG; Luo, S; Jelovsek, JE
Published in: Neurourol Urodyn
January 2022

AIMS: Develop models to predict outcomes after intradetrusor injection of 100 or 200 units of onabotulinumtoxinA in women with non-neurogenic urgency urinary incontinence (UUI). METHODS: Models were developed using 307 women from two randomized trials assessing efficacy of onabotulinumtoxinA for non-neurogenic UUI. Cox, linear and logistic regression models were fit using: (1) time to recurrence over 12 months, (2) change from baseline daily UUI episodes (UUIE) at 6 months, and (3) need for self-catheterization over 6 months. Model discrimination of Cox and logistic regression models was calculated using c-index. Mean absolute error determined accuracy of the linear model. Calibration was demonstrated using calibration curves. All models were internally validated using bootstrapping. RESULTS: Median time to recurrence was 6 (interquartile range [IQR]: 2-12) months. Increasing age, 200 units of onabotulinumtoxinA, higher body mass index (BMI) and baseline UUIE were associated with decreased time to recurrence. The c-index was 0.63 (95% confidence interval [CI]: 0.59, 0.67). Median change in daily UUIE from baseline at 6 months was -3.5 (IQR: -5.0, -2.3). Increasing age, lower baseline UUIE, 200 units of onabotulinumtoxinA, higher BMI and IIQ-SF were associated with less improvement in UUIE. The mean absolute error predicting change in UUIE was accurate to 1.6 (95% CI: 1.5, 1.7) UUI episodes. The overall rate of self-catheterization was 17.6% (95% CI: 13.6%-22.4%). Lower BMI, 200 units of onabotulinumtoxinA, increased baseline postvoid residual and maximum capacity were associated with higher risk of self-catheterization. The c-index was 0.66 (95% CI: 0.61, 0.76). The three calculators are available at http://riskcalc.duke.edu. CONCLUSIONS: After external validation, these models will assist clinicians in providing more accurate estimates of expected treatment outcomes after onabotulinumtoxinA for non-neurogenic UUI in women.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurourol Urodyn

DOI

EISSN

1520-6777

Publication Date

January 2022

Volume

41

Issue

1

Start / End Page

432 / 447

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Urinary Incontinence, Urge
  • Urinary Incontinence
  • Urinary Bladder, Overactive
  • Treatment Outcome
  • Humans
  • Female
  • Botulinum Toxins, Type A
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hendrickson, W. K., Xie, G., Rahn, D. D., Amundsen, C. L., Hokanson, J. A., Bradley, M., … Jelovsek, J. E. (2022). Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women. Neurourol Urodyn, 41(1), 432–447. https://doi.org/10.1002/nau.24845
Hendrickson, Whitney K., Gongbo Xie, David D. Rahn, Cindy L. Amundsen, James A. Hokanson, Megan Bradley, Ariana L. Smith, et al. “Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.Neurourol Urodyn 41, no. 1 (January 2022): 432–47. https://doi.org/10.1002/nau.24845.
Hendrickson WK, Xie G, Rahn DD, Amundsen CL, Hokanson JA, Bradley M, et al. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women. Neurourol Urodyn. 2022 Jan;41(1):432–47.
Hendrickson, Whitney K., et al. “Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.Neurourol Urodyn, vol. 41, no. 1, Jan. 2022, pp. 432–47. Pubmed, doi:10.1002/nau.24845.
Hendrickson WK, Xie G, Rahn DD, Amundsen CL, Hokanson JA, Bradley M, Smith AL, Sung VW, Visco AG, Luo S, Jelovsek JE. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women. Neurourol Urodyn. 2022 Jan;41(1):432–447.
Journal cover image

Published In

Neurourol Urodyn

DOI

EISSN

1520-6777

Publication Date

January 2022

Volume

41

Issue

1

Start / End Page

432 / 447

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Urinary Incontinence, Urge
  • Urinary Incontinence
  • Urinary Bladder, Overactive
  • Treatment Outcome
  • Humans
  • Female
  • Botulinum Toxins, Type A
  • 3209 Neurosciences
  • 3202 Clinical sciences